Watson Pharmaceuticals, Inc. (NYSE: WPI) is a leading integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, brand and biologic pharmaceutical products. We operate and manage our business as three operating segments: Global Generics, Global Brands and Anda Distribution. Our largest commercial market is the United States, followed by our key international markets including Western Europe, Canada, Asia/Pacific, South America and South Africa. As of December 31, 2010 we marketed approximately 160 generic prescription pharmaceutical product families and approximately 30 brand pharmaceutical product families in the U.S., and a significant number of product families internationally. Our Anda Distribution Division distributes products for over 200 suppliers and is focused on providing next-day delivery and responsive service to its customers.

Stock Quote WPI (Common Stock) Exchange NYSE (US Dollar) Price $71.96 Change (%)   0.57 (0.80%) Volume 2,478,305 Data as of 05/16/12 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Stock Chart

Date Title   May.09.12 Watson Announces Formation of Global Integration Management Office to Support Pending Actavis Acquisition - Marc Lehnen, Ph.D., Named Senior Vice President, Global Integration Management PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has created a Global Integration Management Office, reporting directly to Paul M. Bisaro, President and Chief Executive Officer, and focusing on planning and implementing the integration of Actavis, following the announcement of Watson's intention to acquire the Zug, Switzerland-based company.  Marc Le...  May.09.12 Watson Confirms Lialda® Patent Challenge - Paragraph IV Litigation Underway - PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g. Watson's ANDA product is a generic version of Shire Development LLC's Lialda®. Shire Development LLC, Shir...  May.04.12 Watson Names Lisa DeFrancesco Vice President, Global Investor Relations PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Lisa M. DeFrancesco has been promoted to the position of Vice President, Global Investor Relations, effective immediately.  In this position, Ms. DeFrancesco reports to Charles Mayr, Chief Communications Officer – Global.  She succeeds Patricia Eisenhaur, who is leaving Watson on June 1, 2012. In this position, Ms. DeFrancesco is responsible for Watson's proactive global investor re...  May.04.12 Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be ...

Corporate Headquarters Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054	Stockholder Information Questions concerning stock ownership may be directed to: Stock Transfer Agent American Stock Transfer and Trust Company 59 Maiden Lane New York, New York 10007 (800) 937-5449 www.amstock.com Independent Accountants PricewaterhouseCoopers LLP Orange County, California
Investor Relations Phone: (862) 261-7488 Email: investor.relations@watson.com
Media Relations Phone: (862) 261-8030 Email: media.relations@watson.com